New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
- Dr. Bruce Moynihan
- Mar 21, 2025
- 4 min read
March (Doctors In Business Journal) - A legal showdown is brewing in the pharmaceutical world, and it revolves around one of the most successful cancer drugs in history—Keytruda. Developed by Merck & Co., Keytruda has become a blockbuster drug, generating nearly half of the company’s annual sales. But now, Merck’s plans to release a new and improved version of the drug are being threatened by a complex patent battle over a seemingly minute but critical enzyme.
Want to read more?
Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.
